mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression

Molecular and Cellular Biology

Volumn 31, Issue 14, 2011, Pages 2787-2801

  Ekim, Bilgen ^a   Magnuson, Brian ^a   Acosta Jaquez, Hugo A ^a   Keller, Jennifer A ^a   Feener, Edward P ^b   Fingar, Diane C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; SHORT HAIRPIN RNA;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PHOSPHO-SPECIFIC; CELL CYCLE; CELL PROLIFERATION; HEK293 CELLS; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PROTEINS; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

MAMMALIA; RAPTORES;

EID: 79960349522     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05437-11     Document Type: Article

References (72)

1. Acosta-Jaquez, H. A., et al. 2009. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol. Cell. Biol. 29: 4308-4324.
2. Alessi, D. R., L. R. Pearce, and J. M. Garcia-Martinez. 2009. New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal. 2:pe27.
3. Avruch, J., et al. 2009. Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem. Soc. Trans. 37:223-226.
4. Bhaskar, P. T., and N. Hay. 2007. The two TORCs and Akt. Dev. Cell 12:487-502.
5. Carriere, A., et al. 2008. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol. 18:1269-1277.
6. Carriere, A., et al. 2011. ERK1/2 phosphorylate Raptor to promote Rasdependent activation of mTOR complex 1 (mTORC1). J. Biol. Chem. 286: 567-577.
7. Chen, J., X. F. Zheng, E. J. Brown, and S. L. Schreiber. 1995. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. U. S. A. 92:4947-4951.
8. Cheng, S. W., L. G. Fryer, D. Carling, and P. R. Shepherd. 2004. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J. Biol. Chem. 279:15719-15722.
9. Chiang, G. G., and R. T. Abraham. 2005. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280:25485-25490.
10. Choi, K. M., L. P. McMahon, and J. C. Lawrence, Jr. 2003. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J. Biol. Chem. 278:19667-19673.
11. Choo, A. Y., and J. Blenis. 2009. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8:567-572.
12. Choo, A. Y., S. O. Yoon, S. G. Kim, P. P. Roux, and J. Blenis. 2008. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-typespecific repression of mRNA translation. Proc. Natl. Acad. Sci. U. S. A. 105:17414-17419.
13. Dann, S. G., A. Selvaraj, and G. Thomas. 2007. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 13:252-259.
14. Dowling, R. J., et al. 2010. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328:1172-1176.
15. Dunlop, E. A., and A. R. Tee. 2009. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal. 21: 827-835.
16. Feldman, M. E., et al. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7:e38.
17. Fingar, D. C., and J. Blenis. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171.
18. Fingar, D. C., et al. 2004. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24:200-216.
19. Fingar, D. C., S. Salama, C. Tsou, E. Harlow, and J. Blenis. 2002. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472-1487.
20. Fonseca, B. D., E. M. Smith, V. H. Lee, C. MacKintosh, and C. G. Proud. 2007. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem. 282: 24514-24524.
21. Foster, K. G., et al. 2010. Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J. Biol. Chem. 285:80-94.
22. Foster, K. G., and D. C. Fingar. 2010. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem. 285: 14071-14077.
23. Garami, A., et al. 2003. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11:1457-1466.
24. Guertin, D. A., and D. M. Sabatini. 2007. Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
25. Guertin, D. A., and D. M. Sabatini. 2009. The pharmacology of mTOR inhibition. Sci. Signal. 2:pe24.
26. Gwinn, D. M., et al. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30:214-226.
27. Hara, K., et al. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189.
28. Holz, M. K., B. A. Ballif, S. P. Gygi, and J. Blenis. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123:569-580.
29. Holz, M. K., and J. Blenis. 2005. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280:26089-26093.
30. Huang, J., and B. D. Manning. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412:179-190.
31. Inoki, K., M. N. Corradetti, and K. L. Guan. 2005. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37:19-24.
32. Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648-657.
33. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
34. Jacinto, E. 2008. What controls TOR? IUBMB Life 60:483-496.
35. Jacinto, E., and A. Lorberg. 2008. TOR regulation of AGC kinases in yeast and mammals. Biochem. J. 410:19-37.
36. Johnston, G. C., J. R. Pringle, and L. H. Hartwell. 1977. Coordination of growth with cell division in the yeast Saccharomyces cerevisiae. Exp. Cell Res. 105:79-98.
37. Jung, C. H., S. H. Ro, J. Cao, N. M. Otto, and D. H. Kim. 2010. mTOR regulation of autophagy. FEBS Lett. 584:1287-1295.
38. Kim, D. H., et al. 2002. mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell 110:163-175.
39. Kim, D. H., D. Sarbassov dos, et al. 2003. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11:895-904.
40. Kim, E., P. Goraksha-Hicks, L. Li, T. P. Neufeld, and K. L. Guan. 2008. Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10:935-945.
41. Kwiatkowski, D. J., and B. D. Manning. 2005. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 14(Spec. No. 2):R251-R258.
42. Laplante, M., and D. M. Sabatini. 2009. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 19:R1046-R1052.
43. Loewith, R., et al. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10:457-468.
44. Ma, L., Z. Chen, H. Erdjument-Bromage, P. Tempst, and P. P. Pandolfi. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179-193.
45. Ma, X. M., and J. Blenis. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318.
46. Manning, B. D., A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10:151-162.
47. McMahon, L. P., K. M. Choi, T. A. Lin, R. T. Abraham, and J. C. Lawrence, Jr. 2002. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol. Cell. Biol. 22:7428-7438.
48. Nave, B. T., M. Ouwens, D. J. Withers, D. R. Alessi, and P. R. Shepherd. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344:427-431.
49. Nojima, H., et al. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278:15461-15464.
50. Oshiro, N., et al. 2007. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 282:20329-20339.
51. Peterson, R. T., P. A. Beal, M. J. Comb, and S. L. Schreiber. 2000. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem. 275:7416-7423.
52. Peterson, T. R., et al. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873-886.
53. Reiling, J. H., and D. M. Sabatini. 2006. Stress and mTORture signaling. Oncogene 25:6373-6383.
54. Roux, P. P., B. A. Ballif, R. Anjum, S. P. Gygi, and J. Blenis. 2004. Tumorpromoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U. S. A. 101:13489-13494.
55. Sancak, Y., et al. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290-303.
56. Sancak, Y., et al. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496-1501.
57. Sancak, Y., et al. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25:903-915.
58. Sato, T., A. Nakashima, L. Guo, and F. Tamanoi. 2009. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J. Biol. Chem. 284:12783-12791.
59. Schalm, S. S., and J. Blenis. 2002. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12:632-639.
60. Schalm, S. S., D. C. Fingar, D. M. Sabatini, and J. Blenis. 2003. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13:797-806.
61. Sekulic, A., et al. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60:3504-3513.
62. Soliman, G. A., et al. 2010. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J. Biol. Chem. 285:7866-7879.
63. Tee, A. R., R. Anjum, and J. Blenis. 2003. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J. Biol. Chem. 278:37288-37296.
64. Tee, A. R., et al. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U. S. A. 99:13571-13576.
65. Tee, A. R., B. D. Manning, P. P. Roux, L. C. Cantley, and J. Blenis. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:1259-1268.
66. Thoreen, C. C., et al. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284:8023-8032.
67. van der Haar, E., S. I. Lee, S. Bandhakavi, T. J. Griffin, and D. H. Kim. 2007. Insulin signaling to mTOR mediated by the AKT/PKB substrate PRAS40. Nat. Cell Biol. 9:316-323.
68. Vilella-Bach, M., P. Nuzzi, Y. Fang, and J. Chen. 1999. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J. Biol. Chem. 274:4266-4272.
69. Wang, L., T. E. Harris, and J. C. Lawrence, Jr. 2008. Regulation of prolinerich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J. Biol. Chem. 283:15619-15627.
70. Wang, L., T. E. Harris, R. A. Roth, and J. C. Lawrence, Jr. 2007. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem. 282:20036-20044.
71. Wang, L., J. C. Lawrence, Jr., T. W. Sturgill, and T. E. Harris. 2009. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J. Biol. Chem. 284:14693-14697.
72. Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. Cell 124:471-484.